December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this early study, the anti-BCMA ADC MEDI228 had manageable toxicity with responses seen at all dose levels in patients with heavily pretreated, relapsed/refractory multiple myeloma.